Stock BIOR BIORA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Biora Therapeutics, Inc.

Equities

BIOR

US74319F3055

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.607 USD -2.08% Intraday chart for Biora Therapeutics, Inc. +1.25% -55.04%
Apr. 04 Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development CI
Apr. 03 Athyrium Capital Management Engages in Discussions with Biora Therapeutics CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biora Therapeutics : Form 8937 – Convertible Note Exchange (December 19, 2023)
PU
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
AQ
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
AQ
Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development
CI
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AQ
Athyrium Capital Management Engages in Discussions with Biora Therapeutics
CI
Top Midday Decliners
MT
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AQ
Transcript : Biora Therapeutics, Inc., Q4 2023 Earnings Call, Mar 26, 2024
Biora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Biora Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
AQ
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
AQ
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset
AQ
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
AQ
Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose Cohorts of Phase 1 Clinical Study of BT-600
CI
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
AQ
Transcript : Biora Therapeutics, Inc. - Special Call
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
AQ
Biora Therapeutics Provides Outlook for 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIOR Stock
  4. News Biora Therapeutics, Inc.